FDMT
4D Molecular Therapeutics Inc
NASDAQ: FDMT · HEALTHCARE · BIOTECHNOLOGY
$8.87
+0.68% today
Updated 2026-04-30
Market cap
$479.88M
P/E ratio
—
P/S ratio
5.63x
EPS (TTM)
$-2.42
Dividend yield
—
52W range
$3 – $12
Volume
0.8M
4D Molecular Therapeutics Inc (FDMT) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $8.24M | $-16.25M | $-36.71M | $-50.91M | $-69.13M | $-86.69M | $-75.79M | $-134.59M | $-109.08M |
| Capital expenditures | $573000.00 | $414000.00 | $3.20M | $1.00M | $9.11M | $11.54M | $2.77M | $3.79M | $536000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $256000.00 | $1.38M | $3.54M | $4.98M | $13.80M | $17.12M | $19.66M | $26.12M | $22.02M |
| Free cash flow | $7.66M | $-16.67M | $-39.91M | $-51.91M | $-78.24M | $-98.22M | $-78.56M | $-138.37M | $-109.62M |
| Investing cash flow | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $227.07M | $-123.72M | $-100.65M | — | — | — |